National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure WRITING GROUP MEMBERS

I. Overview of Heart Failure e99A. Context of Biochemical Marker Testing inHeart Failure e99B. Background and Definition of Terms e100C. B-type Natriuretic Peptide (BNP) and Amino-Terminal proB-Type Natriuretic Peptide(NT-proBNP) Metabolism and Measurement . . . .e100II. Use of Biochemical Markers in the InitialEvaluation of Heart Failure e101A. Diagnosis of Heart Failure e1011. BNP and NT-proBNP for Diagnosis of AcuteDecompensated Heart Failure e1022. BNP or NT-proBNP for Confirmation of theHeart Failure Diagnosis e103B. Risk Stratification of Heart Failure e1031. Risk stratification of Patients With andWithout Heart Failure Using BNP orNT-proBNP e1032. Risk Stratification of Patients With HeartFailure Using Cardiac Troponin e104III. Use of Biochemical Markers in Screening forCardiac Dysfunction e104A. BNP or NT-proBNP for Screening HeartFailure and Dysfunction e104B. Approaches for Screening for CardiacDysfunction e104IV. Use of Biochemical Markers in GuidingManagement of Heart Failure e105A. Monitoring Therapy Using BNP orNT-proBNP Guidance e105V. References e105